Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03344861 · ClinicalTrials.gov registry record · Phase 1
Safety of PDT-Photofrin® Prior to Lung Surgery
A Phase 1 study, sponsored by Concordia Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03344861 is a Phase 1 study that has completed, run by Concordia Laboratories. The registered enrollment target is 10 participants.
The verdict
NCT03344861, a Phase 1 study, has completed, sponsored by Concordia Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This research study is being conducted to assess the safety of PDT in subjects with peripherally located malignant tumors in lung parenchyma prior to surgical resection. It will involve up to 10 sites in USA. Participation will last 4 months.
Interventions
- DRUG Porfimer Sodium
- DEVICE Fiber optic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2019-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03344861
The ClinicalTrials.gov registry entry for NCT03344861 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concordia Laboratories, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Porfimer Sodium is the first listed.
NCT03344861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03344861 about?
NCT03344861 is a clinical study titled "Safety of PDT-Photofrin® Prior to Lung Surgery". This research study is being conducted to assess the safety of PDT in subjects with peripherally located malignant tumors in lung parenchyma prior to surgical resection. It will involve up to 10 sites in USA. Participation will last 4 months.
What is the current status of trial NCT03344861?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-08-14. Estimated completion is 2019-03-22.
What interventions are being tested in trial NCT03344861?
The interventions under investigation include: Porfimer Sodium (DRUG), Fiber optic (DEVICE).
Who is sponsoring clinical trial NCT03344861?
This trial is sponsored by Concordia Laboratories, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.